Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Erysipelas
New research on erysipelas from A.J. Dasilva and co-authors summarized
May 21st, 2008
According to recent research from Sao Carlos, Brazil, "Erysipelothrix rhusiopathiae, the causative agent of swine erysipelas, was cultivated in a 5-L stirred and aerated bioreactor under different dissolved oxygen tensions (0%, 5%, and 30% of saturation) for evaluation of the influence of oxygen on cell growth as well as on the production of the main antigenic component of the vaccine against erysipelas, a 64-69 kDa protein (SpaA). The microorganism presented different growth profiles for different aeration conditions." "However, at the end of the batch cultivations, similar cell concentrations were obtained under the studied conditions. In order to maximize biomass...
Source: Vaccine Weekly (2008-05-21)
|
